Zanamivir hydrate (CAS 551942-41-7)
QUICK LINKS
Zanamivir is a synthetic compound designed to target and inhibit the neuraminidase enzyme, which plays a role in the viral replication process of influenza viruses. By binding to the active site of neuraminidase, zanamivir effectively prevents the release of new viral particles from infected cells, thereby halting the spread of the virus within the host organism. This specific mechanism of action makes it useful for research into viral life cycles, offering insights into the development of novel antiviral strategies. Its use in various studies has contributed to a deeper understanding of influenza pathogenesis and the molecular interactions between viral proteins and host cell components, providing a foundation for the exploration of therapeutic targets and the prevention of viral dissemination in populations.
Zanamivir hydrate (CAS 551942-41-7) References
- Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza. | Gaur, AH., et al. 2010. N Engl J Med. 362: 88-9. PMID: 20032317
- Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model. | Hurt, AC., et al. 2010. Antiviral Res. 87: 361-6. PMID: 20603155
- Oseltamivir, zanamivir and amantadine in the prevention of influenza: a systematic review. | Jackson, RJ., et al. 2011. J Infect. 62: 14-25. PMID: 20950645
- Characterization and in vitro evaluation of intestinal absorption of liposomes encapsulating zanamivir. | Boonyapiwat, B., et al. 2011. Curr Drug Deliv. 8: 392-297. PMID: 21235479
- Quantification of the anti-influenza drug zanamivir in plasma using high-throughput HILIC-MS/MS. | Lindegardh, N., et al. 2011. Bioanalysis. 3: 157-65. PMID: 21250845
- Synthesis of acylguanidine zanamivir derivatives as neuraminidase inhibitors and the evaluation of their bio-activities. | Lin, CH., et al. 2013. Org Biomol Chem. 11: 3943-8. PMID: 23695381
- Effects of formulation and operating variables on zanamivir dry powder inhalation characteristics and aerosolization performance. | Yang, Y., et al. 2014. Drug Deliv. 21: 480-6. PMID: 24491208
- Oseltamivir-zanamivir combination therapy is not superior to zanamivir monotherapy in mice infected with influenza A(H3N2) and A(H1N1)pdm09 viruses. | Pizzorno, A., et al. 2014. Antiviral Res. 105: 54-8. PMID: 24583158
- Preparation, characterization and pulmonary pharmacokinetics of a new inhalable zanamivir dry powder. | Cai, X., et al. 2016. Drug Deliv. 23: 1962-71. PMID: 26066037
- Characteristics and mortality of severe influenza cases treated with parenteral aqueous zanamivir, United Kingdom, October 2009 to January 2011. | Cleary, PR., et al. 2019. Influenza Other Respir Viruses. 13: 44-53. PMID: 30137684
- Design, synthesis and biological evaluation of novel zanamivir derivatives as potent neuraminidase inhibitors. | Cheng, LP., et al. 2018. Bioorg Med Chem Lett. 28: 3622-3629. PMID: 30389293
- Selection of avian influenza A (H9N2) virus with reduced susceptibility to neuraminidase inhibitors oseltamivir and zanamivir. | Kode, SS., et al. 2019. Virus Res. 265: 122-126. PMID: 30910698
- Enabling oral delivery of antiviral drugs: Double emulsion carriers to improve the intestinal absorption of zanamivir. | Debotton, N., et al. 2022. Int J Pharm. 629: 122392. PMID: 36379395
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Zanamivir hydrate, 100 mg | sc-477991 | 100 mg | $390.00 |